Study of Effectiveness and Implementation of a Mental Health Intervention With Conflict-affected Communities in Ukraine
Depression, PostTraumatic Stress Disorder
About this trial
This is an interventional treatment trial for Depression
Eligibility Criteria
Inclusion Criteria:
- Ukrainian adults (age 18 or older) who are either Internally Displaced Persons (IDPs) or military veterans of the conflict is East Ukraine, and their adult family members.
- A score of 7 or above on the locally validated depression scale AND a score of 4 or above on the locally validated function scale
- A score of 9 or above on the locally validated PTS scale AND a score of 4 or above on the locally validated function scale
- Living in or around the 3 study sites for the duration of the study (at least 6 months) and able to regularly attend at least one of the locations where CETA is available for duration of treatment.
Exclusion Criteria:
- Our definition of "veteran" excludes people who identify as veterans but are still active (i.e., active duty) in the Ukrainian military.
- Active thoughts and plans of suicidality or symptoms of psychosis requiring immediate referral to professional psychiatric services.
- Factors identified at baseline that preclude full participation, including: unstable and severe medical, psychiatric or drug use problem that currently necessitates inpatient treatment.
Sites / Locations
- National University of Kyiv Mohyla Academy
- National University of Kyiv Mohyla Academy
- National University of Kyiv Mohyla Academy
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
No Intervention
Full CETA
Brief CETA
Wait-Control
Full CETA participants will complete 12 CETA sessions. this is the same version of CETA that has been tested in other sites. They will be monitored weekly for clinical purposes (symptoms and safety) during treatment. they will also receive monthly research assessments (research outcomes) for 6 months after baseline assessment and commencement of treatment.
Brief CETA participants is a new shorter version of CETA that has the same content as Full CETA but provided in fewer sessions. Each participant will complete 5 CETA sessions and will be monitored weekly for clinical purposes (symptoms and safety) during treatment and thereafter monthly for research purposes (research outcomes) for 6 months after baseline assessment and commencement of treatment.
Wait-control participants will undergo monthly monitoring after enrollment in the study for research purposes (research outcomes) for 6 months after baseline assessment.